By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Exploring the Difficulties of Beginning a Family: Individual Experiences - 2People with depression can treat themselves at home with new device
- 3Instructions to Pick the Right Senior Protection Plan.
- 4IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- 5Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- What to expect from the planets in 2026 — key dates and sky events
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- What's your biological age? Experts explain the benefits and risks of at-home tests
- Wedding trip Objections in the US
- Tehran synagogue damaged by missile strike according to Iranian media
- What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- Nepal’s youngest premier sworn in after releasing new rap song about unity
- The most effective method to Examine a Cellular breakdown in the lungs Finding with Family
- Iran-backed Iraqi militias attack Kurdistan over 450 times since beginning of war
